Gapping up
In reaction to strong earnings/guidance: SANM +11.8%, CIT +11.8%, CMG +10.6%, WWD +7.6%, STLD +7.5%, TGTX +5.4%, (also announces preliminary clinical results from its ongoing Phase I study of TG-1101 (ublituximab): 100% of CLL/SLL patients had significant nodal reduction with either a normalization of or =80% reduction in Blood Lymphocyte Count), HLX +4.8%, ARMH+4.8%, CROX +4.6%, PII +4.4%, CYS +3.7%, MOSY +3%, LMT +2.5%, CMCSA +2.2%, DPZ +2.2%, CNC +2.1%, PKG +2%, UTX +1.3%, CNI +1.1%, RF +0.5%, STT +0.4%, NFLX +0.3%, .
M&A news: GTIV +0.9% (announces receipt of acquisition proposal from Kindred Healthcare (KND)).
Select alt energy related names showing strength after German Govt issued research awards: FCEL +5%, KNDI +4.2%, PLUG +3.5%.
Select semi peers trading higher after TXN and ARMH earnings: STM +2%, AMD +1.1%, MU +0.8%.
Select oil/gas related names showing strength following strength in Crude oil market: TOT +1.3%, RDS.A +0.9%, BP +0.5%.
Other news: RSH +7.2% (still checking), FBRC +6.6% ( announces self tender offer to purchase up to one mln shares, or about 9.9%, of its outstanding common stock, at a price of not less than $28 and not more than $29 per share), SNTA +5.7% (announces advancement of Ganetespib into Phase 3 Extension of AML LI-1 study for patients with AML and High-Risk MDS; follows positive interim analysis of Phase 2 results), TGTX +5.4% (announced preliminary clinical results from ongoing Phase I study of TG-1101 (ublituximab): 100% of CLL/SLL patients had significant nodal reduction with either a normalization of or =80% reduction in Blood Lymphocyte Count), APA +4.4% (reports that Jana Partners would like APA to sell off international business), GST +3.6% (reported 43% increase in mid-year proved reserves), GPRO +2.7% (still checking), GALE +2.5% (enters into definitive agreement to license U.S. rights for Zuplenz (ondansetron) oral soluble film), RDC +2.2% (Blue Harbour Group discloses 6.5% stake in SC 13D filing; expects to continue to engage in discussions with management and the board), MM +1.3% (following Yahoo (YHOO) acquisition of mobile-analytics co Flurry; MM is a mobile advertising platform company), EVGN +1.3% (co and Marrone Bio Innovations (MBII) sign multi-year collaborative agreement; joint discovery efforts to lead to novel insect control solutions), ERIC +1.1% (chosen as sole supplier of Claro's LTE network in Costa Rica), FITB +1% (Fifth Third disclosed share repurchase agreement with Morgan Stanley),AAPL +0.9% (requested that suppliers produce 80 mln large screen iPhones, according to reports (AAPL reports tonight after the close)).
Analyst comments: AXL +1% (upgraded to Neutral from Underweight at JP Morgan), QSII +0.9% (initiated with a Buy at Topeka Capital Markets ), HBAN +0.5% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
In reaction to strong earnings/guidance: SANM +11.8%, CIT +11.8%, CMG +10.6%, WWD +7.6%, STLD +7.5%, TGTX +5.4%, (also announces preliminary clinical results from its ongoing Phase I study of TG-1101 (ublituximab): 100% of CLL/SLL patients had significant nodal reduction with either a normalization of or =80% reduction in Blood Lymphocyte Count), HLX +4.8%, ARMH+4.8%, CROX +4.6%, PII +4.4%, CYS +3.7%, MOSY +3%, LMT +2.5%, CMCSA +2.2%, DPZ +2.2%, CNC +2.1%, PKG +2%, UTX +1.3%, CNI +1.1%, RF +0.5%, STT +0.4%, NFLX +0.3%, .
M&A news: GTIV +0.9% (announces receipt of acquisition proposal from Kindred Healthcare (KND)).
Select alt energy related names showing strength after German Govt issued research awards: FCEL +5%, KNDI +4.2%, PLUG +3.5%.
Select semi peers trading higher after TXN and ARMH earnings: STM +2%, AMD +1.1%, MU +0.8%.
Select oil/gas related names showing strength following strength in Crude oil market: TOT +1.3%, RDS.A +0.9%, BP +0.5%.
Other news: RSH +7.2% (still checking), FBRC +6.6% ( announces self tender offer to purchase up to one mln shares, or about 9.9%, of its outstanding common stock, at a price of not less than $28 and not more than $29 per share), SNTA +5.7% (announces advancement of Ganetespib into Phase 3 Extension of AML LI-1 study for patients with AML and High-Risk MDS; follows positive interim analysis of Phase 2 results), TGTX +5.4% (announced preliminary clinical results from ongoing Phase I study of TG-1101 (ublituximab): 100% of CLL/SLL patients had significant nodal reduction with either a normalization of or =80% reduction in Blood Lymphocyte Count), APA +4.4% (reports that Jana Partners would like APA to sell off international business), GST +3.6% (reported 43% increase in mid-year proved reserves), GPRO +2.7% (still checking), GALE +2.5% (enters into definitive agreement to license U.S. rights for Zuplenz (ondansetron) oral soluble film), RDC +2.2% (Blue Harbour Group discloses 6.5% stake in SC 13D filing; expects to continue to engage in discussions with management and the board), MM +1.3% (following Yahoo (YHOO) acquisition of mobile-analytics co Flurry; MM is a mobile advertising platform company), EVGN +1.3% (co and Marrone Bio Innovations (MBII) sign multi-year collaborative agreement; joint discovery efforts to lead to novel insect control solutions), ERIC +1.1% (chosen as sole supplier of Claro's LTE network in Costa Rica), FITB +1% (Fifth Third disclosed share repurchase agreement with Morgan Stanley),AAPL +0.9% (requested that suppliers produce 80 mln large screen iPhones, according to reports (AAPL reports tonight after the close)).
Analyst comments: AXL +1% (upgraded to Neutral from Underweight at JP Morgan), QSII +0.9% (initiated with a Buy at Topeka Capital Markets ), HBAN +0.5% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)